Table 2.
HCC risk models developed in chronic hepatitis B patients treated with antiviral agents
| HCC risk model | Country or area | Patients | Antiviral agent ETV/TDF/others | Variables used in the HCC risk prediction |
Number of variables | Reference | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age | Sex | Cirrhosis | LSM | Others | ||||||
| PAGE-B | Europe | 1,325 | ETV or TDF | √ | √ | PLT | 3 | [27] | ||
| mPAGE-B | Korea | 2,001 | ETV or TDF | √ | √ | Albumin, PLT | 4 | [28] | ||
| PAGE-B-LS | Korea | 1,211 | 754/457/- | √ | √ | √ | PLT | 4 | [32] | |
| mREACH-B | Korea | 192 | 192/-/- | √ | √ | √ | ALT | 4 | [33] | |
| HCC-RESCUE | Korea | 990 | 990/-/- | √ | √ | √ | 3 | [30] | ||
| APA-B | Taiwan | 883 | 883/-/- | √ | PLT | 3 | [31] | |||
| CAMD | Asia | 23,851 | 22,971/880/- | √ | √ | √ | DM | 4 | [29] | |
| AASL | Korea | 944 | 601/342/- | √ | √ | √ | Albumin | 4 | [6] | |
| REAL-B | USA and Asia | 5,365 | 3,683/593/1,089 | √ | √ | √ | DM, PLT, AFP, alcohol use | 7 | [36] | |
HCC, hepatocellular carcinoma; ETV, entecavir; TDF, tenofovir disoproxil fumarate; LSM, liver stiffness measurement; PLT, platelet; DM, diabetes melltus; AFP, alpha-fetoprotein.